Component
Intramyocellular lipid content
Intramyocellular lipid content. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Subjects randomized to chromium had lower intramyocellular lipid measurements in the substudy.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/chromium-research/20022616.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2", "start_char": 0, "end_char": 1864, "text_sha256": "0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2"}
- experimental_model
- Randomized supplementation with euglycemic-clamp and tissue-lipid substudy
- exposure
- 1,000 µg chromium/day or placebo; responders classified by ≥10% change in insulin sensitivity
- limitations
- Response-defined subgroup comparisons can be affected by regression to the mean and post-treatment selection. They do not validate a deficiency test or a prospective rule for choosing treatment.
- nutrient_topic
- Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium
- organism
- Human with type 2 diabetes across a range of phenotypes
- plain_language
- A muscle-lipid measurement changed, offering a possible research lead rather than a proven universal mediator.
- primary_references
- [chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023
- tissue_or_cell_type
- Insulin sensitivity, muscle/liver lipid and chromium measurements
Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1095–1106
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized supplementation with euglycemic-clamp and tissue-lipid substudy · source_derived_draft · unverified_draft
### chromium-human-muscle-lipid Subjects randomized to chromium had lower intramyocellular lipid measurements in the substudy. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A muscle-lipid measurement changed, offering a possible research lead rather than a proven universal mediator. organism: Human with type 2 diabetes across a range of phenotypes tissue_or_cell_type: Insulin sensitivity, muscle/liver lipid and chromium measurements experimental_model: Randomized supplementation with euglycemic-clamp and tissue-lipid substudy limitations: Response-defined subgroup comparisons can be affected by regression to the mean and post-treatment selection. They do not validate a deficiency test or a prospective rule for choosing treatment. exposure: 1,000 µg chromium/day or placebo; responders classified by ≥10% change in insulin sensitivity evidence_span: {"source_cache": "artifacts/chromium-research/20022616.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2", "start_char": 0, "end_char": 1864, "text_sha256": "0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2"} [chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.